Who Might Qualify

Some clinic pages are already suggesting that this dose won’t be for everyone. The higher strength may be reserved for people who have:

• Already been on 2.4 mg for at least 16–20 weeks

• Achieved less than 5% total weight loss in that time

• Tolerated 2.4 mg without major side effects

That criterion hasn’t yet been confirmed by official regulators, but it’s a strong hint of how prescribers may use the 7.2 mg option once it’s available.

Why It Matters

If approved, 7.2 mg Wegovy could give people another tool when weight loss plateaus, without having to switch to a different GLP-1. For some, it might mean finally reaching health goals that felt out of reach at 2.4 mg.

At the same time, higher doses bring questions about access, affordability, and whether health systems like the NHS will cover them. For now, this is one to watch closely as regulators make their decisions.

A new, higher dose of Wegovy is officially on the horizon, and it’s already sparking questions across the GLP-1 world. Novo Nordisk has submitted its 7.2 mg weekly dose to the European Medicines Agency (EMA), with results showing even greater weight-loss potential than the 2.4 mg dose currently on the market.

So what’s actually happening, and when might you see this new option available in the UK?

From Trials to Real Life

The big evidence comes from Novo Nordisk’s STEP UP trial, which followed people with obesity but without diabetes for 72 weeks. The results were eye-catching: on average, people taking the new 7.2 mg dose lost around 21% of their body weight, compared with about 17.5% on the existing 2.4 mg dose.

One in three participants on the higher dose lost at least a quarter of their body weight, a milestone that until now has mostly been associated with bariatric surgery. Side effects looked similar to what’s already known with Wegovy: mainly nausea, constipation, or fatigue, with a small number of people stopping treatment because of them.

Where Things Stand Now

In July 2025, Novo Nordisk officially submitted the new 7.2 mg dose to the EMA for approval. That means it’s under regulatory review in Europe, with decisions expected late 2025 or early 2026 if all goes smoothly.

For now, it’s not yet approved in the UK, Europe, or the US, so if you see clinics listing 7.2 mg on their websites, that’s future-planning rather than something you can order today.